El interés en corto de Global X DAX Germany ETF da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Global X DAX Germany ETF. Los datos de interés en corto se actualizan cada dos semanas.

Global X DAX Germany ETF (NASDAQ:DAX), Informe de interés en corto

Global X DAX Germany ETF

Industrials

Technology

Financial Services

Consumer Cyclical

Other

Communication Services

Utilities

Basic Materials

Healthcare

Consumer Defensive

Real Estate

The Fund invests at least 80 percent of its total assets in the securities of the DAX Index (DAX Index or Index) and in American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs) based on the securities in the Underlying Index. The Fund's 80 percent investment policy is non-fundamental and requires 60 days prior written notice to shareholders before it can be changed. The Fund's investment objective and Underlying Index may be changed without shareholder approval.

Sap Se

Siemens Ag-reg

Deutsche Telekom Ag-reg

Airbus Se

Mercedes-Benz Group AG

Deutsche Boerse Ag

Deutsche Bank-Rg

Global X Dax Germany ETF

News

Eurozone

Emerging Market ETFs

Politics

Global

Markets

ETFs

CDU/CSU gana las elecciones en Alemania con el 28,5 %. El DAX y el euro reaccionan, pero persisten dudas sobre la coalición.

Elecciones en Alemania: triunfo de los conservadores impulsa al DAX y al euro

DAEX

Daxor Corp

LCII

LCI Industries Acquires Freedman Seating, Expanding Lippert's Reach In Transportation Vehicle Market

LGI Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGIH#NASDAQ">LGIH</a>) reported quarterly earnings of $0.43 per share which missed the analyst consensus estimate of $0.63 by 31.75 percent. This is a 40.28 percent decrease over earnings of $0.72 per share from the same period last year. The company reported quarterly sales of $351.42 million which missed the analyst consensus estimate of $366.45 million by 4.10 percent. This is a 10.09 percent decrease over sales of $390.85 million the same period last year.

Earnings

Earnings Misses

LGIH

LGI Homes Q1 Adj. EPS $0.43 Misses $0.63 Estimate, Sales $351.42M Miss $366.45M Estimate

Financial Guidance 2025 Guidance: PayPal is maintaining full year guidance due to uncertainty in the global macro environment despite a strong start to the year.&nbsp;

Guidance

PYPL

PayPal Holdings Affirms FY2025 Adj EPS Guidance $4.95-$5.10 vs $5.01 Est.; Sees Q2 Adj EPS $1.29-$1.31 vs $1.21 Est.; Says Guidance Unchanged Amid Global Economic Uncertainty, Despite A Strong Start To The Year

Rosenblatt analyst Barton Crockett maintains Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) with a Buy and maintains $20 price target.

Price Target

Analyst Ratings

Rosenblatt Maintains Buy on Viant Technology, Maintains $20 Price Target

Biotech

General

TVTX

Travere Therapeutics And CSL Vifor Announce Standard European Commission Approval Of FILSPARI For IgA Nephropathy

CGEM

Cullinan Therapeutics Announced That The Company Is Initiating A Study Of CLN-978 In Patients With Sjögren's Disease In The U.S

<a href="https://www.globenewswire.com/Tracker?data=z4BvZbQWX7PceEc36Af6HN5ny_R9Tyu4VqPcLv8rjHvviJ4c1Ea5AFWM6LImHc3G-yesisVeVvNbDYBRkhLP3vlRHrtKAK4cG4Igju5ZFgonjqBw-e3MG-E6R8il5Jba">Cullinan Therapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that the Company is initiating a study of CLN-978 in patients with Sjögren's disease (SjD) in the U.S. The Company previously received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) Application clearance to study the CD19 T cell engager in patients with moderate to severe systemic lupus erythematosus (SLE) and European Medicines Agency (EMA) approval to study CLN-978 in active, difficult-to-treat rheumatoid arthritis.
The trial will enroll patients with active, moderate to severe Sjögren's disease who fulfill the 2016 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification criteria and are positive for anti-SSA/RO antibodies and/or rheumatoid factor. The dose escalation scheme will be similar to the SLE study. The primary objective of the study is to evaluate the safety and tolerability of CLN-978 in patients with SjD. Secondary objectives include pharmacokinetics, pharmacodynamics, immunogenicity, and effect on disease activity. The Company expects to initiate the study this quarter.

Cullinan Launches Study for Treatment Aimed at Sjögren's Patients

Matthew Harbaugh named Chief Financial Officer; management team fully staffed ahead of spin-off
Change to future Board Chair announced
WILMINGTON, Del., April 29, 2025 /PRNewswire/ --&nbsp;DuPont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) today announced Qnity Electronics, Inc. ("Qnity") as the name of the planned independent Electronics public company that will be created through the intended spin-off of its Electronics business&#x2A;. As a pure-play electronics materials company, Qnity will be one of the largest and broadest solutions providers to the semiconductor and electronics industries enabling advanced computing, smart technologies and connectivity.
DuPont also announced that Matthew Harbaugh will join the company effective May 1, 2025, and will be the Chief Financial Officer of Qnity.
 &nbsp;

DuPont Unveils Qnity Electronics As Planned Independent Public Company In Electronics Spin-Off; Names Matthew Harbaugh CFO Of Qnity, Effective May 1, 2025

Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) raises FY2025 Adj EPS guidance from $1.59-$1.69 to $1.61-$1.70 vs $1.46 analyst estimate. Raises FY2025 sales outlook from $5.30 billion-$5.50 billion to $5.40 billion-$5.60 billion vs $5.43 billion estimate.

OPCH

Option Care Health Raises FY2025 Adj EPS Guidance from $1.59-$1.69 to $1.61-$1.70 vs $1.46 Est; Raises FY2025 Sales Guidance from $5.30B-$5.50B to $5.40B-$5.60B vs $5.43B Est

Dividends

First Commonwealth Financial Declared Quarterly Dividend Of $0.135 Per Share, Which Represents A 3.9% Increase From The Previous Quarter. The Cash Dividend Is Payable On May 23 To Shareholders Of Record As Of May 9

AEVA

Aeva Unveils Eve 1D: First FMCW-Based Laser Displacement Sensor Targeting $4B Industrial Automation Market

NWTG

Newton Golf Company Announces The Launch Of Its Newest Shaft Family, Newton Fast Motion, Now Available For Purchase At A Suggested Retail Price Of $325

The two new interval funds employ a thoughtful and deliberate approach, designed from the ground up to deliver blended public-private markets exposure with a risk, return and liquidity profile driven by input from financial advisors and a focus on investor needs and outcomes. Defining features include:
<ul>
<li>Public credit and private credit exposures combined into a single, holistic solution: over time, and subject to market conditions, each fund will seek to allocate approximately 60% of net assets to public fixed income and 40% to private credit consisting of direct lending and asset-based finance investments.</li>
<li>Improved liquidity relative to standalone alternatives: quarterly repurchase offers up to 10% of the fund's outstanding shares at net asset value (NAV). Most interval funds offer 5% quarterly liquidity1.</li>
<li>Highly competitive total expense ratios2:
<ul>
<li>Capital Group KKR Core Plus+ at 84 basis points</li>
<li>Capital Group KKR Multi-Sector+ at 89 basis points</li>
</ul>
</li>
<li>Low investment minimum of $1,000 for all share classes.</li>
</ul>

KKR, Capital Group To Expand Exclusive Strategic Partnership, Launch 2 Public-Private Investment Solutions

Needham analyst Ryan Koontz assumes F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) with a Buy rating and announces Price Target of $320.

Initiation

FFIV

Needham Assumes F5 at Buy, Announces Price Target of $320

Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $0.30 by 33.33 percent. This is a 14.29 percent increase over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $1.33 billion which beat the analyst consensus estimate of $1.26 billion by 5.91 percent. This is a 16.32 percent increase over sales of $1.15 billion the same period last year.

Earnings Beats

Option Care Health Q1 Adj. EPS $0.40 Beats $0.30 Estimate, Sales $1.33B Beat $1.26B Estimate

<a href="https://www.veeva.com/">Veeva Systems</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) today announced <a href="https://www.veeva.com/AI">Veeva AI</a>, a major new initiative that adds AI to the Veeva Vault Platform and Veeva applications to help life sciences companies automate tasks and improve employee productivity using AI Agents and AI Shortcuts. Veeva AI provides a fast and efficient way to introduce application-specific AI Agents based on large language models (LLMs) into existing Veeva applications and enable end users with AI Shortcuts. Veeva AI will work in all Veeva applications across all major areas, including clinical, regulatory, safety, quality, medical, and commercial.
&nbsp;
Veeva AI Agents can be deployed quickly with high impact because they understand the Veeva application context, have application-specific prompts and safeguards, and have direct, secure access to Veeva application data, documents, and workflows. Customers can configure and extend Veeva-delivered AI Agents and build custom AI Agents to address company-specific use cases. AI Agents can be used through a chatbot user interface or called via the AI API.
Veeva AI Shortcuts empower end users with the ability to easily set up personal AI-powered automations to accomplish frequent user-specific tasks such as helping with workflows, generating insights, or researching a topic.

VEEV

Veeva Adds AI to Make Drug Development and Health Research Faster and Smarter

LITM

Snow Lake Energy Announces That Snow Lake's Joint Venture With Global Uranium And Enrichment Limited Has Significantly Expanded The Pine Ridge Uranium Project Landholding In The Powder River Basin In Wyoming

First Commonwealth Q1 2025 Adj. EPS $0.32, Inline, Sales $118.36M Beat $117.50M Estimate

YELP

Yelp Says It Introduced New AI-powered Features To Streamline Hiring Service Pros And Enhance The Dining Experience

Rosenblatt analyst Steve Frankel maintains Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) with a Buy and lowers the price target from $12 to $11.

HLIT

Rosenblatt Maintains Buy on Harmonic, Lowers Price Target to $11

Comments

Global X DAX Germany ETF

Interés en corto

Global X DAX Germany ETF (NASDAQ:DAX), Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL